/PRNewswire/ Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK,.
Verastem (NASDAQ:VSTM – Get Rating) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, MarketWatch Earnings reports. Verastem had a negative return on equity of 74.56% and a negative net margin of 3,468.09%. NASDAQ VSTM traded up $0.04 on Wednesday, […]
StockNews.com downgraded shares of Verastem (NASDAQ:VSTM – Get Rating) from a hold rating to a sell rating in a research report released on Monday. Separately, Truist Financial initiated coverage on Verastem in a report on Wednesday, March 9th. They set a buy rating and a $6.00 price objective for the company. One investment analyst has […]